{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:52:26Z","timestamp":1782298346803,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.nmd.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T23:38:24Z","timestamp":1533857904000},"page":"865-867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution"],"prefix":"10.1016","volume":"28","author":[{"given":"Anton","family":"Ivanyuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Garc\u00eda Segarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-5536","authenticated-orcid":false,"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jacquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-6681","authenticated-orcid":false,"given":"Christopher J.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-3661","authenticated-orcid":false,"given":"Clemens","family":"Bloetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.nmd.2018.08.004_bib0001","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.nmd.2018.08.004_bib0002","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2018.08.004_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"10101","key":"10.1016\/j.nmd.2018.08.004_bib0004","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"issue":"9979","key":"10.1016\/j.nmd.2018.08.004_bib0005","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.nmd.2018.08.004_bib0006","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval.","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2018.08.004_bib0007","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","volume":"1","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2018.08.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/928385","article-title":"Optimizing bone health in duchenne muscular dystrophy","volume":"2015","author":"Buckner","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"11","key":"10.1016\/j.nmd.2018.08.004_bib0009","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.nmd.2010.07.272","article-title":"170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27\u201329 November 2009, Naarden, The Netherlands","volume":"20","author":"Quinlivan","year":"2010","journal-title":"Neuromuscul Disord."},{"issue":"7","key":"10.1016\/j.nmd.2018.08.004_bib0010","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00198-016-3515-9","article-title":"The management of osteoporosis in children","volume":"27","author":"Ward","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.nmd.2018.08.004_bib0011","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/BOR.0000000000000423","article-title":"Osteoporosis in childhood","volume":"29","author":"Vierucci","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.nmd.2018.08.004_bib0012","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1542\/peds.2010-1666","article-title":"Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy","volume":"127","author":"Gordon","year":"2011","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.nmd.2018.08.004_bib0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.apmr.2004.04.021","article-title":"Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy","volume":"86","author":"Hawker","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"10.1016\/j.nmd.2018.08.004_bib0014","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.23948","article-title":"Bone density and alendronate effects in Duchenne muscular dystrophy patients","volume":"49","author":"Houston","year":"2014","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.nmd.2018.08.004_bib0015","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.nmd.2018.08.004_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.nmd.2018.08.004_bib0017","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jocd.2014.01.004","article-title":"Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions","volume":"17","author":"Bishop","year":"2014","journal-title":"J Clin Densitom"},{"issue":"7","key":"10.1016\/j.nmd.2018.08.004_bib0018","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.nmd.2018.08.004_bib0019","series-title":"Fosamax\u00ae prescribing information","year":"2012"},{"key":"10.1016\/j.nmd.2018.08.004_bib0020","series-title":"Proceedings of the Endocrine Society's 92nd Annual Meeting, June 19\u201322","article-title":"Rhabdomyolysis associated with intravenous zoledronic acid infusion for the treatment of postmenopausal osteoporosis","author":"Schaefer","year":"2010"},{"key":"10.1016\/j.nmd.2018.08.004_bib0021","unstructured":"Uppsala Monitoring Centre, WHO. WHO global Individual Case Safety Report (ICSR) database (VigiLyze). Available at http:\/\/vigilyze.who-umc.org. Accessed 29 March 2017."},{"issue":"11","key":"10.1016\/j.nmd.2018.08.004_bib0022","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1210\/jc.2015-2680","article-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience","volume":"100","author":"George","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.nmd.2018.08.004_bib0023","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0002-9343(92)90740-3","article-title":"Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia","volume":"92","author":"Singhal","year":"1992","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.nmd.2018.08.004_bib0024","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1211\/jpp.61.06.0011","article-title":"Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts","volume":"61","author":"Nishiguchi","year":"2009","journal-title":"J Pharm Pharmacol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617314864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617314864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:08:08Z","timestamp":1760774888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896617314864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0960896617314864"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2018.08.004","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}